A major cyber security challenge, aimed at educating and inspiring the next generation of cyber defenders from across the UK and US, will be held at the University of Cambridge next week.
In this piece for The Conversation, Carlos López-Gómez from Cambridge's Institute for Manufacturing, discusses the role that small and medium-sized businesses might play in a post-Brexit economy.
An open source, 3D-printable microscope that forms the cornerstone of rapid, automated water testing kits for use in low and middle-income countries, has helped a Cambridge researcher and his not-for-profit spin-out company win the top prize in this year’s Vice-Chancellor’s Impact Awards at the University of Cambridge.
Solutions designed by secondary school students as part of an innovative classroom design and technology programme could help reduce the number of unnecessary deaths from childhood asthma.
An on-the-spot, low-cost diagnostic test for leptospirosis (Weil's disease), a bacterial infection recognised as a neglected disease by the World Health Organization, could save lives in developing countries where there is little or no access to medical pathology laboratories and specialist technicians.
Artificial bile ducts grown in lab and transplanted into mice could help treat liver disease in children03 Jul 2017
Cambridge scientists have developed a new method for growing and transplanting artificial bile ducts that could in future be used to help treat liver disease in children, reducing the need for liver transplantation.
Nanotechnology is creating new opportunities for fighting disease – from delivering drugs in smart packaging to nanobots powered by the world’s tiniest engines.
Researchers are working with pharmaceutical companies to make improvements across the whole supply chain, from how a pill is made to the moment it is swallowed by the patient.
How will precision medicine define 21st-century therapeutics? What will future healthcare look like? And what actually lies ‘beyond the pill’? Professor Chris Lowe, inaugural Director of the Cambridge Academy of Therapeutic Sciences, takes the long view on the future of therapeutics.